Protagenic Therapeutics Inc Stock News

Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced that it expects to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 in the near future, following a delay attributable to ...

Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of first dose injection for all study subjects in the multiple-dose portion of its ongoing Phase I clinical t...

NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.

NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to Protagenic shareholders. Upon completion of the proposed transaction, Protagenic shareholders are expected to own approximately 35% of the combined company. Halper Sadeh encourages Protagenic shareholders t...

NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused ...

Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, today announced that the Company's Board of Directors has approved a 1-for-14 reverse stock split of the Company's issued and outstandi...